November 5, 2021 – Pfizer announced on Friday that its pill to treat Covid-19 had been found in a key clinical trial to be highly effective at preventing severe illness among at-risk people who received the drug soon after they exhibited symptoms.
The antiviral pill is the second of its kind to demonstrate efficacy against Covid. It appears to be more effective than a similar offering from Merck, which is awaiting federal authorization.
Pfizer’s pill, which will be sold under the brand name Paxlovid, cut the risk of hospitalization or death by 89 percent when given within three days after the start of symptoms.
Pfizer said an independent board of experts monitoring its clinical trial recommended that the study be stopped early because the drug’s benefit to patients had proved so convincing. The company said it planned to submit the data as soon as possible to the Food and Drug Administration to seek authorization for the pill to be used in the United States.
“The results are really beyond our wildest dreams,” said Annaliesa Anderson, a Pfizer executive who led the drug’s development. She expressed hope that Paxlovid “can have a big impact on helping all our lives go back to normal again and seeing the end of the pandemic.”
The treatment could become available in the next few months, though supplies are likely to be limited at first. The Pfizer and Merck pills are both geared toward patients regarded as high-risk, such as those above the age of 60 or with conditions like obesity that make them more susceptible to severe consequences from Covid.
Follow the travel news – Traveltalksplatform is the number 1 news site to stay updated on amazing travel facts, the latest news, events, incentive ideas, MICE news, job opportunities and shows.
Specially composed for the travel industry, you will find the latest travel facts at your fingertips.
Copyright © 2021 e-motions international
We assume no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.